{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/generalized-anxiety-disorder/","result":{"data":{"firstChapter":{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 15b8167b-762d-474f-af37-965e1f877c81 --><h1>Generalized anxiety disorder: Summary</h1><!-- end field 15b8167b-762d-474f-af37-965e1f877c81 -->","htmlStringContent":"<!-- begin item 15aa4efd-8917-4c06-8a39-f09e3cb7ac27 --><!-- begin field b9f9623b-303b-40ac-9c16-a519987c6adc --><ul><li>Generalized anxiety disorder (GAD) is characterized by disproportionate, pervasive, uncontrollable, and widespread worry and a range of somatic, cognitive, and behavioural symptoms that occur on a continuum of severity.<ul><li>Onset of symptoms is insidious, often unremitting, and can be lifelong.</li><li>While some people will present with obvious anxiety, others will initially present with somatic symptoms such as muscle tension or insomnia.</li></ul></li><li>The somatic, cognitive, and behavioural symptoms of GAD can severely impair day-to-day functioning and commonly present in association with other depressive and physical health comorbidities.</li><li>The aetiology of anxiety disorders is multifactorial and includes environmental stressors, genetic factors, chronic illness, and substance abuse.</li><li>Anxiety disorders as a diagnostic category are the most common psychiatric disorders. It is estimated that about 25% of adults will suffer an anxiety disorder at some point in their life.<ul><li>The disorder can develop at any point, although it is most commonly seen in adults between 35 and 55 years of age.</li></ul></li><li>A stepped-care approach should be used for the management of GAD.<ul><li>If comorbidities such as depression are present, the clinician should decide which is the most significant (in terms of severity and likelihood of response to treatment) and treat that first.</li><li>If the anxiety symptoms are mild, a period of active monitoring should initially be undertaken.</li><li>If symptoms have not resolved following a period of active monitoring, a low-intensity psychological intervention which includes individual facilitated or non-facilitated self-help or psychoeducational group therapy should be offered.</li><li>In the presence of marked functional impairment, or if symptoms have not resolved with low-intensity psychological interventions, either a high-intensity psychological intervention (such as applied relaxation or cognitive behavioural therapy), or drug therapy should be offered, depending on the person's wishes.<ul><li>If the person chooses drug therapy, selective-serotonin reuptake inhibitors (SSRIs) are recommended first-line.</li><li>If an SSRI cannot be tolerated, a serotonin-noradrenaline reuptake inhibitor (SNRI) is a possible alternative.</li><li>If an SSRIs and SNRIs are contraindicated or not tolerated, pregabalin can be considered.</li></ul></li><li>Referral for specialist treatment should be arranged if GAD is complex and there is an inadequate response to treatment (high intensity psychological interventions and drug treatments) or very marked functional impairment or high risk of self-harm, suicide or self-neglect.</li></ul></li></ul><!-- end field b9f9623b-303b-40ac-9c16-a519987c6adc --><!-- end item 15aa4efd-8917-4c06-8a39-f09e3cb7ac27 -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","aliases":[],"chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","slug":"management","fullItemName":"Management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","aliases":[],"topicSummary":"Generalized anxiety disorder (GAD) is disproportionate, pervasive, uncontrollable, and widespread worry and a range of somatic, cognitive symptoms","lastRevised":"Last revised in February 2021","nextPlannedReviewBy":"2022-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2022-09","nextPlannedReviewByDisplay":"September 2022","specialities":[{"id":"460cf76a-c057-55d8-a7ab-50fe9463f7da","name":"Mental health","slug":"mental-health"}],"chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","slug":"management","fullItemName":"Management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111"}},"staticQueryHashes":["3666801979"]}